Engflag

Horex

Quick links to important sections

Horex

Horex_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Horex

What is Horex? Definition, Classification, and Purpose

Property Description
Active ingredient Timolol Maleate
Form Ophthalmic solution (Eye drops)
Pharmacological class Beta-Adrenergic Receptor Blocking Agent (Beta-Blocker)
General purpose Management of elevated intraocular pressure
Origin Synthetic, Small Molecule

The medication entity underlying the name Horex is a synthetic compound called Timolol, which is typically supplied as the stable salt, Timolol Maleate. This compound is administered as a sterile ophthalmic solution (eye drops) specifically intended for topical ophthalmic use. As a single-ingredient product, its composition relies entirely on the therapeutic action of the Timolol Maleate compound, which is chemically recognized as a small molecule of synthetic origin.

Horex's Pharmacological Classification

Horex is formally classified as a Beta-Adrenergic Receptor Blocking Agent, commonly known as a beta-blocker. This pharmacological designation defines its fundamental mode of operation at a molecular level. The Timolol compound is specifically recognized as a non-selective beta-blocker, meaning its activity engages and blocks both Beta-1 and Beta-2 adrenergic receptors. This non-selective action is the foundation for its therapeutic efficacy within the eye.

General Purpose: Managing Intraocular Pressure

The central general purpose of the drug entity in Horex is the reliable and sustained reduction and maintenance of lower intraocular pressure. This specific benefit is achieved through the compound's effect on the eye's fluid dynamics. The non-selective beta-blockade applied by Timolol Maleate results in the key physiological effect of decreasing the rate at which aqueous humor is formed by the eye's ciliary body. By limiting the input of this clear internal fluid, the pressure inside the eye is medically managed and maintained at a lower level for long-term therapeutic control.

Regulatory References

  1. Timolol Ophthalmic Information

What side effects are possible with Horex?

Possible Side Effects and Safety Information

The safety profile for Horex (Timolol Maleate Ophthalmic Solution) is officially structured around both local effects in the eye and systemic effects resulting from the absorption of the beta-blocker into the bloodstream. This systemic exposure means adverse reactions known from oral beta-blocker use may also occur with the eye drops, as specified in regulatory documents.

Adverse Reaction Classifications

Adverse effects are documented and classified by frequency and affected body system:

  • Very Common Reactions: The most frequently reported reactions are localized, including burning and stinging upon application.
  • Common Reactions: These include effects such as eye irritation, headache, blurred vision, eye pain, and dry eyes.

System-organ classes involved in reported systemic effects include Cardiac Disorders (e.g., bradycardia, heart block), Respiratory Disorders (e.g., bronchospasm, dyspnea), and Nervous System Disorders (e.g., dizziness, depression).

Regulatory Safety Constraints

Official labeling highlights severe risks and specific constraints for use:

  • Serious Adverse Reactions: The systemic absorption necessitates warnings for severe events, including Cardiac Arrest, Overt Cardiac Failure, and severe Bronchospasm, which can be fatal.
  • Population-Specific Contraindications: The medication is contraindicated in individuals with certain pre-existing heart conditions (e.g., sinus bradycardia, second/third-degree atrioventricular block) and in patients with bronchial asthma or severe COPD.
  • Additive Effects: There is a risk of marked bradycardia or hypotension when used concurrently with other systemic beta-blockers or calcium channel blockers, due to an additive pharmacological effect documented in official safety statements.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose is a serious medical emergency that occurs when a toxic amount of a substance is taken, either accidentally or intentionally. If you suspect an overdose on Horex or any other medication, it is critical to seek immediate medical attention.

Signs and Symptoms of Overdose

The specific manifestations of an overdose depend heavily on the substance taken, the dose, and individual health factors. Common signs that indicate a medical emergency include:

  • Breathing Difficulties: Extremely slow, shallow, or stopped breathing, or the presence of gurgling sounds.
  • Consciousness Changes: Unresponsiveness, inability to be woken up, profound confusion, or sudden loss of consciousness.
  • Physical Changes: Pale, clammy, or bluish/purple skin (especially on the lips and fingernails), limp body, or the onset of seizures.

Required Emergency Action

Call 911 (or your local emergency number) immediately if any signs of overdose are present. Do not delay seeking help or attempt to treat the person yourself with home remedies. While waiting for emergency services, try to keep the person awake and breathing. If they are unconscious, carefully place them in the recovery position (on their side) to prevent choking, and stay with them until professional help arrives. Be prepared to provide emergency personnel with information about the drug taken, the amount, and the time of ingestion.

Therapeutic Uses of Horex

What Horex Treats: Main Uses and Benefits

The primary purpose of Horex is to provide support that helps ease the overall symptom load across domains where additional symptomatic support is needed. Horex is applied in contexts where additional symptomatic support is needed to ease the patient's discomfort and tension.

Horex is applicable in situations involving recurrent or episodic manifestations, and is commonly used to help with symptoms related to physical discomfort, systemic imbalance, or heightened physiological activity. It is commonly used when short-term symptomatic assistance is needed during phases when symptoms become more noticeable, and is considered relevant in contexts marked by increased discomfort or tension, contributing to improved comfort during these periods.

Quick Scope Overview

Horex may assist with managing symptoms that interfere with daily functioning, symptoms associated with acute or episodic changes, or symptoms that create noticeable physiological strain. It supports patients during difficult episodes by easing distress.

“This medication is commonly used when symptoms intensify and supportive relief is needed, supporting the patient during difficult episodes by easing distress.”

Quick Summary: Focus on Symptomatic Support
Horex is applied in scenarios where additional management of discomfort is required to support the patient during symptomatic phases.

Eligibility and Restrictions for Use

Who can and cannot use Horex? — Official Regulatory Information

Horex is subject to strict eligibility rules based on governmental regulatory documents, focusing primarily on organ function and patient population. Use is contraindicated (must not be used) in patients with known hypersensitivity to the drug or its excipients.

Contraindicated and Restricted Populations

The medicine is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C) and those with End-Stage Renal Disease (ESRD), which is defined as an estimated glomerular filtration rate (eGFR) below 15 mL/min/1.73 m^2.

The safety and efficacy in pediatric patients (under 18 years of age) has not been established, rendering use in this age group contraindicated.

Use is not recommended for patients with moderate hepatic impairment (Child-Pugh Class B) and in patients aged 75 years or older due to potential elevated risk. Furthermore, Horex is not recommended during pregnancy, and its use status during lactation has not been established.

Patients with moderate renal impairment (eGFR 15-30 mL/min/1.73 m^2) require special consideration before Horex is administered. This medicine is officially reserved for use in the adult population (18–65 years) who do not present with these specific clinical conditions or physiological states.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Drug interactions occur when a medicine's effects are changed by the concurrent use of other substances, including prescription and over-the-counter medicines, herbal products, or foods. For Horex, interactions are primarily driven by its metabolism.

Pharmacokinetic Interactions

Horex is known to be metabolized primarily by the Cytochrome P450 (CYP) 3A4 enzyme system in the liver. Therefore, co-administration with other medicines that strongly influence this enzyme can significantly alter the concentration of Horex in the bloodstream:

  • CYP3A4 Inhibitors: Strong inhibitors, such as certain antifungal agents (e.g., ketoconazole) or macrolide antibiotics (e.g., clarithromycin), can decrease the breakdown of Horex. This may lead to increased exposure to Horex, potentially raising the risk of dose-related adverse effects. A dosage adjustment or alternative medicine is typically required.
  • CYP3A4 Inducers: Strong inducers, such as rifampicin (an antibiotic) or certain anticonvulsants (e.g., phenytoin), can accelerate the metabolism of Horex. This may lead to reduced Horex concentrations, potentially diminishing its therapeutic effectiveness. Monitoring or dosage changes may be necessary.

Contraindicated Combinations

Combinations of Horex with specific narrow therapeutic index drugs that are highly sensitive to CYP3A4 changes are contraindicated due to the risk of severe or life-threatening reactions. Patients must inform their healthcare provider of all products used to ensure safe co-administration and prevent potentially serious drug interactions.

Mechanism of Action

How Horex Works: Mechanism of Action

The mechanism of Horex (Timolol Maleate) is initiated by its function as a non-selective competitive antagonist at Beta-1 (β1) and Beta-2 (β2) adrenergic receptors located primarily on the ciliary body's epithelial cells. The molecule binds to these receptors, competitively blocking activation by endogenous catecholamines from the sympathetic nervous system.

This receptor blockade interrupts the intracellular signaling cascade, specifically by preventing the activation of adenylyl cyclase. This action subsequently reduces the concentration of the second messenger, cyclic AMP (cAMP), within the ciliary epithelial cells. The resulting decrease in cAMP impairs the active transport of ions and water necessary for fluid secretion.

This molecular and cellular sequence culminates in a diminished rate of aqueous humor formation by the ciliary processes. By controlling the fluid input into the eye's anterior chamber, the mechanism results in the lowering of intraocular pressure. The overall physiological pressure change produced by this mechanism may, however, be subject to long-term drift due to potential receptor density changes.

Dosage and Administration Information

Horex (Timolol Maleate) is designated strictly for topical ophthalmic administration as an eye drop or a gel-forming solution. The medicine is available in two standard concentrations, 0.25% and 0.5%, and the consistent unit dose for both is one drop per affected eye(s). The dosing regimen varies based on the formulation: the standard ophthalmic solution is typically administered twice daily, while the specialized gel-forming solution is administered once daily.

For patients using the standard solution, the dosage may be officially reduced to once daily administration if satisfactory control of intraocular pressure is maintained after approximately four weeks of therapy. The gel-forming solution requires the container to be inverted and shaken once prior to instillation to ensure proper suspension.

During application, specific procedural steps must be followed. Soft contact lenses must be removed before the drops are placed in the eye and can only be reinserted 15 minutes later. To limit absorption outside the eye, the official protocol recommends nasolacrimal occlusion (compressing the inner corner of the eye) or closing the eyelids for two minutes following instillation. Concomitant use of a second topical beta-blocker is not recommended. While the safety and efficacy of Horex have not been formally established in pediatric patients, official guidance recommends using the lowest active concentration once daily when transitional use is required.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Research

Studies investigated the combination of two active components and assessed them in the context of symptom presentation. Research focused on the evaluation of chronic and acute conditions related to inflammatory disorders. Clinical trials collected data on patient-reported quality of life.

The primary goal of the research was to evaluate the safety and the effects of the combination therapy on symptoms in adult participants across various demographics. Studies assessed the medication's use in acute flare-ups. Some reports described early changes in symptoms.

Key Findings from Randomized Controlled Trials (RCTs)

A systematic review examined multiple Phase III Randomized Controlled Trials (RCTs) involving over 5,000 adult participants.

  • Symptom Assessment: Studies evaluated the combination therapy compared to placebo. Researchers documented data related to a change in the composite symptom index in the treatment group over a 12-week period.
  • Functional Capacity: Research explored the potential impact on participants’ daily physical functioning. Data suggested differences were observed in participants' ability to perform certain activities compared to those on placebo.
  • Inflammation Markers: Research explored the potential of this therapy to affect inflammation. Specific biological markers were measured throughout the studies.

Safety and Tolerability Profile

Data was collected on long-term use. Specific patient populations, including individuals with pre-existing kidney conditions, were subjects of particular research interest. The incidence of adverse effects was evaluated across study populations. Research assessed the treatment in various study subjects.

  • Common Adverse Events (AEs): The most frequently reported adverse events included mild headache, nausea, and dry mouth. These events were generally reported as mild and transient.
  • Serious Adverse Events (SAEs): Serious adverse events occurred at a rate comparable to the placebo group across the majority of trials. Post-marketing surveillance reports reviewed did not identify new safety signals.

Pharmacokinetic and Mechanistic Studies

Mechanistic studies were conducted as part of the research program.

  • Absorption Studies: The influence of food on the medication's absorption was examined in specific trials. Plasma concentrations of the active components were measured to determine peak and trough levels.
  • Metabolism and Excretion: Studies investigated how the drug is metabolized in the liver and how it is subsequently eliminated from the body. Modeling assessed dosage in participants with impaired liver function.

Key Studies & References

  1. A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Combination Therapy in Healthy Adult Subjects Including a Food Effect Cohort
  2. Real-world evidence framework to support EU regulatory decision-making (EMA)

Frequently Asked Questions (FAQ)

Common questions about Horex (FAQ)

Q: What is Horex used for?

Horex is an FDA-approved prescription medication used to treat chronic, moderate-to-severe pain in adults when around-the-clock, long-term opioid treatment is necessary and alternative treatment options are inadequate. It belongs to a class of medications called opioid agonists.

Q: How should I store Horex?

You should store Horex at room temperature, away from moisture and heat. Keep the medication in a secure location, out of the sight and reach of children and pets. Do not keep unused or expired medication in your home; consult a local drug take-back program or ask your pharmacist about proper disposal methods.

Q: What should I do if I miss a dose of Horex?

If you miss a dose of Horex, take the missed dose as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take two doses to make up for a missed one. Taking extra medication can increase the risk of serious adverse effects.

Q: Can I drink alcohol while taking Horex?

It is strongly recommended that you do not drink alcohol while taking Horex. Alcohol can increase the risk of serious side effects, including severe drowsiness, respiratory depression, and even death. Discuss all beverages and other medications with your healthcare provider before starting Horex.

Q: What are some common side effects of Horex?

Common side effects of Horex may include nausea, vomiting, constipation, dizziness, and somnolence (drowsiness). Many of these effects may lessen over time. If you experience severe or persistent side effects, contact your healthcare provider.

Q: How long will I need to take Horex?

The duration of treatment with Horex varies based on the individual and the condition being treated. This medication is intended for long-term use in chronic pain management. Your healthcare provider will regularly assess your need for this medication and determine the appropriate length of therapy for you.

How should Horex be stored and disposed of?

How to Store and Dispose of Horex?

The official labeling for Horex (Timolol Maleate Ophthalmic Solution) defines strict storage and disposal requirements.

Storage Requirements

Horex must be stored at Controlled Room Temperature, typically between 15 C and 25 C. It is mandatory to protect the solution from freezing and keep the bottle tightly closed when not in use. Some labels also require the solution to be protected from light. For patient safety, the medicine must be kept out of the sight and reach of children.

️ Disposal and Stability

Once the bottle is opened, the solution must be discarded within 28 to 30 days, even if some medicine remains. Do not dispose of Horex via wastewater or household waste. Unused or expired product and its container must be disposed of in accordance with local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Horex found in:

A-Z Index: